ERBB2 and neoplasm: Marquez et al. showed that increased tumor uptake of 89Zr-pertuzumab in the presence of unlabeled trastuzumab14, implying its better affinity toward HER2 and the potential of using pertuzumab-derived ADC to treat patients.